// App-Quantinova.ai

S148 : VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

Researchers

Presenter

  • Othman Al-Sawaf

Principal Investigators

  • Can Zhang

  • Sandra Robrecht

  • Naomi Chang

  • Anna-Maria Fink

  • Eugen Tausch

  • Christof Schneider

  • Matthias Ritgen

  • Karl-Anton Kreuzer

  • Brenda Chyla

  • Barbara Eichhorst

  • Yanwen Jiang

  • Stephan Stilgenbauer

  • Michael Hallek

  • Kirsten Fischer

Medical Centers

  • Genentech, Inc.,South San Francisco, CA,Stati Uniti

  • Department I

  • Department II of Internal Medicine,University of Schleswig Holstein,K

  • Roche Products Ltd,Welwyn Garden City,Reino Unido

  • Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, University of Cologne, Cologne, Germany

  • Department of Internal Medicine III,Ulm University Hospital,Ulm,Allemagne

  • Genentech, Inc.,South San Francisco, CA,Stati Uniti

  • Roche Products Ltd,Welwyn Garden City,Royaume-uni

  • Department of Internal Medicine III,Ulm University Hospital,Ulm,Allemagne

  • Department II of Internal Medicine,University of Schleswig Holstein,K

  • Genentech, Inc.,South San Francisco,Verenigde Staten

  • AbbVie, Inc., North Chicago, IL

  • AbbVie Inc ,North Chicago, IL,Vereinigte Staaten

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Roche Products Ltd,Welwyn Ga

  • AbbVie Inc ,North Chicago, IL,Vereinigte Staaten

  • Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany

  • Department of Internal Medicine III,Ulm University Hospital,Ulm,Allemagne

  • Department of Internal Medicine III,Ulm University Hospital,Ulm,Allemagne

  • Genentech Inc., San Francisco, United States

  • AbbVie Inc ,North Chicago, IL,Estados Unidos

  • Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf,

  • Roche Products Ltd,Welwyn Garden City,Verenigd Koninkrijk

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • AbbVie Inc ,North Chicago, IL,États-unis

  • Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany

  • Department II of Internal Medicine,University of Schleswig Holstein,K

  • AbbVie Inc., North Chicago, Illinois, United States

  • Genentech, Inc.,South San Francisco, CA,Stati Uniti

  • Genentech, Inc., South San...

  • Roche Products Ltd,Welwyn Garden City,Reino Unido

  • Roche Products Ltd,Welwyn Garden City,Verenigd Koninkrijk

  • Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, University of Cologne, Cologne, Germany

  • Department of Internal Medicine III,Ulm University Hospital,Ulm,Allemagne

  • AbbVie Inc ,North Chicago, IL,Stati Uniti

  • Genentech, Inc.,South San Francisco,Verenigde Staten

Locations

  • United Kingdom

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • chlorambucil

  • Venetoclax

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved